newsfilter
← Latest News
GlobeNewswire·

Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting

PRAX
  • Praxis Precision Medicines will present preclinical & clinical data on its precision epilepsy pipeline at the American Epilepsy Society Annual Meeting in Atlanta from December 5-9, 2025.
  • The company will host a scientific exhibit & interactive sessions at Booth #217 to discuss progress on vormatrigine, relutrigine, & elsunersen.
  • Late-breaking presentation 1.503 on Saturday, December 6, will share full RADIANT study results showing vormatrigine rapidly reduces seizures in adults with treatment-resistant epilepsy.
  • Presentation 1.38 on Saturday, December 6, will detail relutrigine's sustained seizure reduction in the EMBOLD open-label extension study.
  • Multiple presentations on Sunday, December 7, & Monday, December 8, will cover the PAC-DEE framework, emergency use of antisense oligonucleotide & sodium channel modulation for SCN2A DEE, relutrigine's potential in Dravet syndrome, vormatrigine's drug-drug interaction profile, & the EMPOWER observational study.
  • Vormatrigine (PRAX-628) is a next-generation small molecule targeting hyperexcitable sodium channels for once-daily oral treatment of focal onset seizures & generalized epilepsy.
  • Relutrigine (PRAX-562) is a first-in-class sodium channel modulator for developmental & epileptic encephalopathies holding FDA Orphan Drug Designation & Rare Pediatric Disease Designation for SCN2A-DEE, SCN8A-DEE, & Dravet syndrome.
  • Elsunersen (PRAX-222) is an antisense oligonucleotide designed to reduce SCN2A gene expression for early-onset SCN2A-DEE, holding FDA Orphan Drug Designation & Rare Pediatric Disease Designation.
  • The company utilizes proprietary Cerebrum™ small molecule & Solidus™ ASO platforms to develop therapies for CNS disorders driven by neuronal excitation-inhibition imbalance.